Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

This phase II clinical trial evaluates the efficacy and tolerability of the non-intensive treatment with venetoclax and the hypomethylating agent azacitidine as compared to the standard of care chemotherapy plus gemtuzumab ozogamicin in newly diagnosed NPM1 mutated AML patients fit for intensive chemotherapy.

Trial Details

NCT ID
NCT05904106
Phase
PHASE2
Sponsor
Technische Universität Dresden
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax plus Azacitidine
  • standard of care chemotherapy plus gemtuzumab ozogamicin
Locations (sample)
  • Essen, North Rhine-Westphalia, Germany|51.45657,7.01228
  • Aachen, Germany|50.77664,6.08342
  • Augsburg, Germany|48.37154,10.89851
  • Chemnitz, Germany|50.8357,12.92922
  • Cologne, Germany|50.93333,6.95

Key Eligibility Criteria

  • A signed informed consent
  • Newly diagnosed CD33-positive AML with NPM1 mutation according to WHO criteria
  • Age 18-70 years
  • Fit for intensive chemotherapy, defined by

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →